| Name | Title | Contact Details |
|---|---|---|
Patrick Phillips |
Chief Operating Officer | Profile |
Mike Lynch |
Executive Director, IT Delivery | Profile |
Matt Edwards |
Sr. Director, IT Operations & Security | Profile |
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations.
Eyenovia is a clinical stage, biopharmaceutical company transforming the delivery of therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. Eyenovia`s breakthrough piezo-dispersion and microdosing technology enable a portfolio of first-in-class, next-generation, micro-therapeutics for the eye designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing therapeutics.
Enzymerx is a Paramus, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our patented and award-winning Highlight® technology makes it easy to use disinfectants correctly.
Exagen Diagnostics Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.